Advanced search
Publication Cover
Clinical Toxicology Volume 55, 2017 - Issue 8
Submit an article Journal homepage
353
Views
13
CrossRef citations to date
0
Altmetric
Short Communication

Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus

Maren Hermanns-ClausenPoisons Information Centre, Centre for Pediatrics, Medical Center – University of Freiburg, Germany; Correspondence[email protected]
View further author information
,
Verena AngererDepartment of Forensic Toxicology, Institute of Forensic Medicine, Medical Center – University of Freiburg, GermanyView further author information
,
Josephine KithinjiPoisons Information Centre, Centre for Pediatrics, Medical Center – University of Freiburg, Germany; View further author information
,
Christina GrumannDepartment of Forensic Toxicology, Institute of Forensic Medicine, Medical Center – University of Freiburg, GermanyView further author information
&
Volker AuwärterDepartment of Forensic Toxicology, Institute of Forensic Medicine, Medical Center – University of Freiburg, GermanyView further author information
Pages 922-924 | Received 29 Jan 2017, Accepted 07 Apr 2017, Published online: 04 May 2017

References

  • European Monitoring Centre for Drugs and Drug Addiction. 25I-NBOMe report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances. [Internet]. Luxembourg: Publications Office; 2014 [cited 2015 Dec 1]. Available from: http://dx.publications.europa.eu/10.2810/5725
  • Nichols DE, Frescas SP, Chemel BR, et al. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem. 2008;16:6116–6123.
  • Stellpflug SJ, Kealey SE, Hegarty CB, et al. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol. 2014;10:45–50.
  • Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol. 2013;51:487–492.
  • Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol. 2013;51:174–177.
  • Kueppers VB, Cooke CT. 25I-NBOMe related death in Australia: a case report. Forensic Sci Int. 2015;249:e15–e18.
  • Lowe LM, Peterson BL, Couper FJ. A case review of the first analytically confirmed 25I-NBOMe-related death in Washington State. J Anal Toxicol. 2015;39:668–671.
  • Shanks KG, Sozio T, Behonick GS. Fatal intoxications with 25B-NBOMe and 25I-NBOMe in Indiana during 2014. J Anal Toxicol. 2015;39:602–606.
  • Caspar AT, Helfer AG, Michely JA, et al. Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS. Anal Bioanal Chem. 2015;407:6697–6719.
  • Poklis JL, Dempsey SK, Liu K, et al. Identification of metabolite biomarkers of the designer hallucinogen 25I-NBOMe in mouse hepatic microsomal preparations and human urine samples associated with clinical intoxication. J Anal Toxicol. 2015;39:607–616.
  • Wohlfarth A, Roman M, Andersson M, et al. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry: metabolism of 25C- and 25I-NBOMe. Drug Test Anal. 2016; [Internet]. [cited 2016 Aug 23]. Available from: http://doi.wiley.com/10.1002/dta.2044
  • Nielsen LM, Holm NB, Leth-Petersen S, et al. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH: characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH. Drug Test Anal. 2016; [Internet]. [cited 2016 Aug 23]. Available from: http://doi.wiley.com/10.1002/dta.2031
  • Poklis JL, Charles J, Wolf CE, et al. High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomed Chromatogr. 2013;27:1794–1800.
  • Glaeser H, Drescher S, Hofmann U, et al. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther. 2004;76:230–238.
  • Maeda K, Takano J, Ikeda Y, et al. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther. 2011;90:263–270.
  • Rickli A, Luethi D, Reinisch J, et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015;99:546–553.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.